Amgen stock holds steady as investors await fresh catalyst
Published on 07/16/2026 at 08:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen (ISIN US0311621009) is a U.S.-listed biotechnology company with a broad portfolio of marketed medicines and pipeline candidates.
Business base
The company operates from Thousand Oaks, California, and trades on Nasdaq under the ticker AMGN. That U.S. listing makes it a familiar large-cap health care name for retail investors following the sector.
Why it matters
Amgen's size and diversified product base give it a different risk profile from smaller biotech peers, where single-program outcomes can dominate the share price. For investors, the key question is how durable the company's established revenue base remains alongside pipeline execution.
Representative product
Repatha is one of Amgen's best-known products and illustrates the company's model: use large-scale commercialization to turn clinical advances into recurring sales. That mix of marketed drugs and development-stage assets is central to the stock's long-term investment case.
Stock snapshot
Amgen stock trades on Nasdaq as a large-cap U.S. health care company.
Amgen stock facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Exchange: Nasdaq
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
